Heart and Vessels

, Volume 31, Issue 8, pp 1247–1256 | Cite as

Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation

  • Daisuke IzumiEmail author
  • Masatoshi Miyahara
  • Naoki Fujimoto
  • Shusuke Fukuoka
  • Masataka Sakai
  • Kaoru Dohi
  • Masaaki Ito
Original Article


Our objective was to clarify whether thrombogenic problems with stent struts are resolved at 3 months after 2nd-generation drug-eluting stent implantation. Twenty-one patients with stable angina pectoris having 28 (22 zotarolimus-eluting, 6 everolimus-eluting) stents with optical coherence tomography (OCT)-guided percutaneous coronary intervention (PCI) were evaluated. Stent strut coverage and malapposition were evaluated by OCT immediately after PCI and at 3-month follow-up. Acute strut malapposition was observed in 26 out of 28 analyzed stents (92.9 %). At 3-month follow-up, 7 (26.9 %) of those 26 stents with strut malapposition were completely resolved, and the mean percentages of uncovered struts and malapposed struts were 8.3 and 2.0 % when analyzed by each individual stent. When analyzing a total of 30,060 struts, 807 struts (2.7 %) demonstrated acute strut malapposition. Among these, 219 struts (27.1 %) demonstrated persistent strut malapposition. On the basis of receiver-operating characteristic curve analysis, a strut-to-vessel (S-V) distance ≤160 µm on post-stenting OCT images was the corresponding cutoff point for resolved malapposed struts (sensitivity 78.1 %, specificity 62.8 %, area under the curve 0.758). The S-V distance of persistent malapposed struts on post-stenting OCT images was longer than that of resolved malapposed struts (235 ± 112 vs. 176 ± 93 µm, p < 0.01). At 3 months after PCI, the prevalence rates of uncovered and malapposed struts were relatively low in 2nd-generation drug-eluting stent. Our results suggest that OCT-guide PCI with an S-V distance ≤160 µm may be recommended especially in patients with planed short-term DAPT.


Strut malapposition Optical coherence tomography Drug-eluting stents 


Compliance with ethical standards

Conflict of interest

All authors declare that they have no potential conflict of interest.


  1. 1.
    Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME, Investigators TAXUS-IV (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350:221–231CrossRefPubMedGoogle Scholar
  2. 2.
    Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, Investigators SIRIUS (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315–1323CrossRefPubMedGoogle Scholar
  3. 3.
    Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678CrossRefPubMedGoogle Scholar
  4. 4.
    Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 297:159–168CrossRefPubMedGoogle Scholar
  5. 5.
    Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Genereux P, Branzi A, Stone GW (2013) Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol 62:1915–1921CrossRefPubMedGoogle Scholar
  6. 6.
    Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmão M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL, Trial Investigators OPTIMIZE (2013) Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 310:2510–2522PubMedGoogle Scholar
  7. 7.
    Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y, Investigators RESET (2012) A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (Real Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 60:1340–1348CrossRefPubMedGoogle Scholar
  8. 8.
    Capodanno D, Angiolillo DJ (2013) Management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Circulation 128:2785–2798CrossRefPubMedGoogle Scholar
  9. 9.
    Guagliumi G, Sirbu V, Musumeci G, Gerber R, Biondi-Zoccai G, Ikejima H, Ladich E, Lortkipanidze N, Matiashvili A, Valsecchi O, Virmani R, Stone GW (2012) Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv 5:12–20CrossRefPubMedGoogle Scholar
  10. 10.
    Lee SY, Hong MK (2013) Stent evaluation with optical coherence tomography. Yonsei Med J 54:1075–1083CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Gutiérrez-Chico JL, Wykrzykowska J, Nüesch E, van Geuns RJ, Koch KT, Koolen JJ, di Mario C, Windecker S, van Es GA, Gobbens P, Jüni P, Regar E, Serruys PW (2012) Vascular tissue reaction to acute malapposition in human coronary arteries: sequential assessment with optical coherence tomography. Circ Cardiovasc Interv 5:20–29CrossRefPubMedGoogle Scholar
  12. 12.
    Jang IK, Bouma BE, Kang DH, Park SJ, Park SW, Seung KB, Choi KB, Shishkov M, Schlendorf K, Pomerantsev E, Houser SL, Aretz HT, Tearney GJ (2002) Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J Am Coll Cardiol 39:604–609CrossRefPubMedGoogle Scholar
  13. 13.
    Ikuta S, Kobuke K, Iwanaga Y, Nakauchi Y, Yamaji K, Miyazaki S (2014) Difference in neointimal coverage at chronic stage between bare metal stent and sirolimus-eluting stent evaluated at stent-strut level by optical coherence tomography. Heart Vessels 29:320–327CrossRefPubMedGoogle Scholar
  14. 14.
    Kim S, Kim JS, Shin DH, Kim BK, Ko YG, Choi D, Cho YK, Nam CW, Hur SH, Jang Y, Hong MK (2013) Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography. Am J Cardiol 111:1–5CrossRefPubMedGoogle Scholar
  15. 15.
    Kim JS, Jang IK, Fan C, Kim TH, Kim JS, Park SM, Choi EY, Lee SH, Ko YG, Choi D, Hong MK, Jang Y (2009) Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv 2:1240–1247CrossRefPubMedGoogle Scholar
  16. 16.
    Hashikata T, Tojo T, Namba S, Kitasato L, Hashimoto T, Kameda R, Shimohama T, Yamaoka-Tojo M, Ako J (2014) Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months’ follow-up: an optical coherence tomography study. Heart Vessels. doi: 10.1007/s00380-014-0598-0 PubMedGoogle Scholar
  17. 17.
    Tu S, Holm NR, Koning G, Huang Z, Reiber JH (2011) Fusion of 3D QCA and IVUS/OCT. Int J Cardiovasc Imaging 27:197–207CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ozaki Y, Kitabata H, Tsujioka H, Hosokawa S, Kashiwagi M, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Takarada S, Kubo T, Kimura K, Tanaka A, Hirata K, Mizukoshi M, Imanishi T, Akasaka T (2012) Comparison of contrast media and low-molecular-weight dextran for frequency-domain optical coherence tomography. Circ J 76:922–927CrossRefPubMedGoogle Scholar
  19. 19.
    Kawamori H, Shite J, Shinke T, Otake H, Matsumoto D, Nakagawa M, Nagoshi R, Kozuki A, Hariki H, Inoue T, Osue T, Taniguchi Y, Nishio R, Hiranuma N, Hirata K (2013) Natural consequence of post-intervention stent malapposition, thrombus, tissue prolapse, and dissection assessed by optical coherence tomography at mid-term follow-up. Eur Heart J Cardiovasc Imaging 14:865–875CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Im E, Kim BK, Ko YG, Shin DH, Kim JS, Choi D, Jang Y, Hong MK (2014) Incidences, predictors, and clinical outcomes of acute and late stent malapposition detected by optical coherence tomography after drug-eluting stent implantation. Circ Cardiovasc Interv 7:88–96CrossRefPubMedGoogle Scholar
  21. 21.
    Inoue T, Shite J, Yoon J, Shinke T, Otake H, Sawada T, Kawamori H, Katoh H, Miyoshi N, Yoshino N, Kozuki A, Hariki H, Hirata K (2011) Optical coherence evaluation of everolimus-eluting stents 8 months after implantation. Heart 97:1379–1384CrossRefPubMedGoogle Scholar
  22. 22.
    Guo N, Maehara A, Mintz GS, He Y, Xu K, Wu X, Lansky AJ, Witzenbichler B, Guagliumi G, Brodie B, Kellett MA Jr, Dressler O, Parise H, Mehran R, Stone GW (2010) Incidence, mechanisms, predictors, and clinical impact of acute and late stent malapposition after primary intervention in patients with acute myocardial infarction: an intravascular ultrasound substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation 122:1077–1084CrossRefPubMedGoogle Scholar
  23. 23.
    Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, Ohba T, Mizuno K (2007) Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol 99:1033–1038CrossRefPubMedGoogle Scholar
  24. 24.
    Terashima M, Kaneda H, Suzuki T (2012) The role of optical coherence tomography in coronary intervention. Korean J Intern Med 27:1–12CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Jang IK, Tearney GJ, MacNeill B, Takano M, Moselewski F, Iftima N, Shishkov M, Houser S, Aretz HT, Halpern EF, Bouma BE (2005) In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation 111:1551–1555CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Inoue T, Shinke T, Otake H, Nakagawa M, Hariki H, Osue T, Iwasaki M, Taniguchi Y, Nishio R, Hiranuma N, Konishi A, Kinutani H, Kuroda M, Hirata K (2014) Impact of strut-vessel distance and underlying plaque type on the resolution of acute strut malapposition: serial optimal coherence tomography analysis after everolimus-eluting stent implantation. Int J Cardiovasc Imaging 30:857–865CrossRefPubMedGoogle Scholar
  27. 27.
    Won H, Shin DH, Kim BK, Mintz GS, Kim JS, Ko YG, Choi D, Jang Y, Hong MK (2013) Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation. Int J Cardiovasc Imaging 29:1255–1263CrossRefPubMedGoogle Scholar
  28. 28.
    Hassan AK, Bergheanu SC, Stijnen T, van der Hoeven BL, Snoep JD, Plevier JW, Schalij MJ, Wouter Jukema J (2010) Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 31:1172–1180CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2015

Authors and Affiliations

  • Daisuke Izumi
    • 1
    Email author
  • Masatoshi Miyahara
    • 2
  • Naoki Fujimoto
    • 3
  • Shusuke Fukuoka
    • 2
  • Masataka Sakai
    • 2
  • Kaoru Dohi
    • 4
  • Masaaki Ito
    • 4
  1. 1.Department of CardiologyJapanese Red Cross Ise HospitalIse-CityJapan
  2. 2.Department of CardiologyMatsusaka Central General HospitalMatsusakaJapan
  3. 3.Department of Molecular and Laboratory MedicineMie University Graduate School of MedicineTsuJapan
  4. 4.Department of Cardiology and NephrologyMie University Graduate School of MedicineTsuJapan

Personalised recommendations